Volume 17, Number 5—May 2011
Dispatch
Probable Non–Vector-borne Transmission of Zika Virus, Colorado, USA
, Kevin C. Kobylinski, Joy L. Chilson Foy, Bradley J. Blitvich, Amelia Travassos da Rosa, Andrew D. Haddow, Robert S. Lanciotti, and Robert B. Tesh
Table A1
Serologic results for 3 patients in whom symptoms of arboviral illness developed, northern Colorado, USA, 2008*
| Serum sample | Viruses/viral antigens tested |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GETV | CHIKV | SINV | ZIKV | DENV1 | DENV2 | DENV3 | DENV4 | YFV | WNV | UGSV | SLEV | TAHV | JCV | LACV | |
| Hemagglutination inhibition test | |||||||||||||||
| Pt1a | 0 | 0 | NT | 5,120 | 2,560 | 640 | 2,560 | 2,560 | 5,120 | 2,560 | 1,280 | NT | 0 | NT | NT |
| Pt1c | 0 | 0 | NT | 5,120 | 1,280 | 320 | 1,280 | 1,280 | 2,560 | 1,280 | 1,280 | NT | 0 | NT | NT |
| Pt2a | 0 | 0 | NT | 1,280 | 160 | 80 | 320 | 320 | 1,280 | 160 | 160 | NT | 0 | NT | NT |
| Pt2c | 0 | 0 | NT | 2,560 | 160 | 80 | 320 | 320 | 1,280 | 160 | 160 | NT | 0 | NT | NT |
| Pt3a | 0 | 0 | NT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NT | 0 | NT | NT |
| Pt3c |
0 |
0 |
NT |
320 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NT |
0 |
NT |
NT |
| Plaque-reduction neutralization test | |||||||||||||||
| Pt1a | NT | <10 | <10 | 10,240 | 80 | 1,280 | 320 | 160 | >20,480 | <10 | NT | 80 | <10 | NT | NT |
| Pt1c | NT | NT | NT | >40,960 | 160 | 230 | 320 | 320 | >40,960 | 160 | NT | NT | NT | NT | NT |
| Pt2a | NT | NT | NT | 10,240 | <20 | 80 | 80 | 40 | 5,120 | NT | NT | NT | NT | NT | NT |
| Pt2c | NT | NT | NT | 40,960 | 80 | 160 | 160 | 160 | 20,480 | 80 | NT | NT | NT | NT | NT |
| Pt3a | NT | NT | NT | 10 | <10 | <10 | <10 | <10 | <10 | <10 | NT | <10 | NT | <10 | <10 |
| Pt3c |
NT |
NT |
NT |
1,280 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
NT |
NT |
NT |
NT |
NT |
| Complement fixation test | |||||||||||||||
| Pt1a | NT | NT | NT | 64/8 | NT | NT | NT | NT | 64/8 | NT | NT | NT | NT | NT | NT |
| Pt1c | NT | NT | NT | 128/32 | NT | NT | NT | NT | 64/8 | NT | NT | NT | NT | NT | NT |
| Pt2a | NT | NT | NT | 16/8 | NT | NT | NT | NT | 16/8 | NT | NT | NT | NT | NT | NT |
| Pt2c | NT | NT | NT | 32/32 | NT | NT | NT | NT | 16/8 | NT | NT | NT | NT | NT | NT |
| Pt3a | NT | NT | NT | 0 | NT | NT | NT | NT | 0 | NT | NT | NT | NT | NT | NT |
| Pt3c | NT | NT | NT | 16/8 | NT | NT | NT | NT | 0 | NT | NT | NT | NT | NT | NT |
*Togaviridae: GETV, Getah virus; CHIKV, chikungunya virus; SINV, Sindbis virus; Flaviviridae: ZIK, Zika virus; DENV, dengue virus; YFV, yellow fever virus; WNV, West Nile virus; UGSV, Uganda S virus; SLEV, St. Louis encephalitis virus; Bunyaviridae: TAHV, Tahyna virus; JCV, Jamestown Canyon virus; LAC, La Crosse virus; pt1, 2, and 3, patients 1, 2, and 3, respectively; a and c, acute-phase and convalescent-phase serum samples, respectively; NT, not tested. Hemagglutination test, numbers are reciprocal of serum dilution inhibiting 4 units of antigen; 0 = negative reaction at a 1:20 dilution. Plaque-reduction neutralization test, numbers refer to neutralizing antibody titers with a 90% cutoff value: titers > positive control serum samples are indicated in boldface. Complement fixation tests, numbers refer to reciprocal of serum titer/reciprocal of antigen titer; 0, negative reaction at <8/<8.